Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/1756-6614-4-10

Language：English   Publishing type：Research paper (scientific journal)  

Obesity is a serious international health problem that increases the risk of several diet-related chronic diseases. The genetic factors predisposing to obesity are little understood. Rcan2 was originally identified as a thyroid hormone-responsive gene. In the mouse, two splicing variants that harbor distinct tissue-specific expression patterns have been identified: Rcan2-3 is expressed predominately in the brain, whereas Rcan2-1 is expressed in the brain and other tissues such as the heart and skeletal muscle. Here, we show that Rcan2 plays an important role in the development of age- and diet-induced obesity. We found that although the loss of Rcan2 function in mice slowed growth in the first few weeks after birth, it also significantly ameliorated age- and diet-induced obesity in the mice by causing a reduction in food intake rather than increased energy expenditure. Rcan2 expression was most prominent in the ventromedial, dorsomedial and paraventricular hypothalamic nuclei governing energy balance. Fasting and refeeding experiment showed that only Rcan2-3 mRNA expression is up-regulated in the hypothalamus by fasting, and loss of Rcan2 significantly attenuates the hyperphagic response to starvation. Using double-mutant (Lep(ob/ob) Rcan2(-/-)) mice, we were also able to demonstrate that Rcan2 and leptin regulate body weight through different pathways. Our findings indicate that there may be an Rcan2-dependent mechanism which regulates food intake and promotes weight gain through a leptin-independent pathway. This study provides novel information on the control of body weight in mice and should improve our understanding of the mechanisms of obesity in humans.

Language：English   Publishing type：Research paper (scientific journal)  

The neurological mouse mutation shambling (shm) exhibits ataxia and hindlimb paresis. Positional cloning of shm showed that it encodes contactin-associated protein (Caspr), which is required for formation of the paranodal junction in myelinated nerves. The shm mutation is a TT insertion in the Caspr gene that results in a frame shift and a premature stop codon at the COOH-terminus. The truncated Caspr protein that is generated lacks the transmembrane and cytoplasmic domains. Here, we found that the nodal/paranodal axoplasm of shm mice lack paranodal junctions and contain large mitochondria and abnormal accumulations of cytoplasmic organelles that indicate altered axonal transport. Immunohistochemical analysis of mutant mice showed reduced expression of Caspr, contactin, and neurofascin 155, which are thought to form a protein complex in the paranodal region; protein 4.1B, however, was normally distributed. The mutant mice had aberrant localization of voltage-gated ion channels on the axolemma of nodal/paranodal regions. Electrophysiological analysis demonstrated that the velocity of saltatory conduction was reduced in sciatic nerves and that the visual response was attenuated in the primary visual cortex. These abnormalities likely contribute to the neurological phenotype of the mutant mice.

Language：English   Publishing type：Research paper (scientific journal)  

The mechanism of diabetes-induced congenital malformation remains to be elucidated. It has been reported that -lipoic acid (LA) prevents neural tube defects (NTDs) in offsprings of rats with streptozotocin-induced diabetes. Here, we evaluate the protective effect of LA against diabetic embryopathy, including NTDs, cardiovascular malformations (CVMs), and skeletal malformations, in mice.
Female mice were rendered hyperglycemic using streptozotocin and then mated with normal male mouse. Pregnant diabetic or non-diabetic mice were treated daily with either LA (100 mg/kg body weight) or saline between gestational days 0 and 18. On day 18, fetuses were examined for congenital malformations.
Plasma glucose levels on day 18 were not affected by LA treatment. No congenital malformations were observed either in the saline-treated or LA-treated non-diabetic group. In the saline-treated diabetic group, 39% of fetuses had external malformations and 30% had NTDs. In the LA-treated diabetic group, the corresponding proportions were 11 and 8%, respectively. LA treatment also decreased the incidence of CVMs from 30-3% and of skeletal malformations from 29-6%.
We conclude that LA can reduce NTDs, CVMs and skeletal malformations in the offspring of diabetic mice at term delivery.

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Event date： 2021.8

Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

Venue：筑波大学（オンライン）  

Event date： 2020.8

Language：Japanese  

Event date： 2018.8

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2017.8

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2014.7

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2007.6

Language：Japanese   Presentation type：Poster presentation  

Country：Japan  

Event date： 2007.6

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Country：Japan  

Event date： 2006.11

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2006.11

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2006.10

Language：English   Presentation type：Poster presentation  

Event date： 2006.10

Language：English   Presentation type：Poster presentation  

Event date： 2006.4

Language：Japanese   Presentation type：Poster presentation  

Country：Japan  

Event date： 2006.4

Language：Japanese   Presentation type：Poster presentation  

Country：Japan  

Event date： 2005.4

Language：English  

Country：Japan  

Event date： 2005.4

Language：Japanese  

Country：Japan  

Event date： 2005.2

Language：Japanese  

Country：Japan  

Event date： 2004.11

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.7

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.7

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.6

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.5

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.2

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2004.2

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2003.12

Language：English   Presentation type：Oral presentation (general)  

Event date： 2003.11

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2003.4

Language：English   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2001.4

Language：English   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 1997.8

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Country：Japan  

Event date： 1996.10

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Country：Japan  

Event date： 1993.1

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Country：Japan  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)